InsuLife Revenue

Pharmaceutical Manufacturing • Oslo, Oslo, Norway • 11-20 Employees

InsuLife revenue & valuation

Annual revenue	$1,112,215
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$3,600,000
Total funding	No funding

Key Contacts at InsuLife

Pål Eriksen

Member Board Of Directors

Åge Nærdal

Chief Executive Officer At Insulife As

Age Nerdal

Chief Executive Officer

Company overview

Headquarters	Oslo, Oslo, Norway
Websites	insulife.com insulife.no
NAICS	3254
Founded	2020
Employees	11-20
Socials

InsuLife Email Formats

InsuLife uses 3 email formats. The most common is {first initial} (e.g., j@insulife.com), used 40% of the time.

Format	Example	Percentage
{first initial}	j@insulife.com	40%
{first name}.{last name}	john.doe@insulife.no	40%
{first initial}.{last name}	j.doe@insulife.com	20%

About InsuLife

InsuLife is a Norwegian company aiming at developing and bringing the unparalleled investigational ILS-2501 apply-on-the-skin based insulin to market. This includes the carrying out of any and all necessary product studies and authorization activities. ILS-2501 will represent an international innovation and paradigm shift. Insulin in apply-on-the-skin form has the potential to fulfill a need for people with diabetes who want to avoid needles and to take insulin in the most practical way. There is no transdermal apply-on-the-skin insulin in the global pharmaceutical market today. InsuLife are developing a novel product with delivery of apply-on-the-skin insulin which will be easy form of administration and efficacy is expected to be comparable to the traditional subcutaneous injections. The Future of Insulin Delivery ILS-2501 aims to be the first transdermal apply-on-the-skin Insulin. Applied directly onto the skin, ILS-2501 eliminates the use of needles. The target of this breakthrough product: Eliminates multiple injections per day Potential for better patient compliance Utilizes unmodified human insulin, a “commodity” drug product enabling cost competitiveness Shows strong indication of stability in room temperature, - no need for refrigeration

Employees by Management Level

Total employees: 11-20

Seniority

Employees

C-Suite

Entry

Director

Employees by Department

InsuLife has 5 employees across 3 departments.

Departments

Number of employees

Funding Data

InsuLife has never raised funding before.

InsuLife Tech Stack

Discover the technologies and tools that power InsuLife's digital infrastructure, from frameworks to analytics platforms.

SiteGround

Hosting

jQuery

JavaScript libraries

CivicTheme

UI frameworks

Nginx

Reverse proxies

PHP

Programming languages

Open Graph

Miscellaneous

Complianz

A/B Testing

WordPress

Blogs

Oxygen

Page builders

RankMath SEO

SEO

Google Analytics

Analytics

MySQL

Databases

Frequently asked questions

InsuLife is located in Oslo, Oslo, NO.

InsuLife generates an estimated annual revenue of $1,112,215. This revenue figure reflects the company's market position and business performance in its industry.

InsuLife has an estimated valuation of $3,600,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

InsuLife was founded in 2020, making it 6 years old. The company has established itself as a significant player in its industry over this time.

InsuLife has approximately 11-20 employees. The company continues to grow its workforce to support its business operations and expansion.